In contrast to currently emerging immunotherapy approach using CAR T cells, our strategy allows tumor-specific targeting of HLA-A*24:02-positive cancer patients, irrespective of antigen-specific expression on cell surface and the type of cancer, and thus TEG011_CD8α therapy has broader applicability towards a substantial amount of cancer patients with HLA-A*24:02-positive haplotype highlighting its therapeutic potential for further clinical application. This evidence concerns the gene CD8A and neoplasm.